Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Athira Pharma ( (ATHA) ) is now available.
On May 29, 2025, Athira Pharma held its Annual Meeting of Stockholders, where approximately 71.58% of the total shares entitled to vote were present or represented by proxy. The stockholders elected three Class II directors, ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2025, and approved amendments to the company’s certificate of incorporation to effect a reverse stock split and reduce the total number of authorized shares of common stock.
The most recent analyst rating on (ATHA) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Athira Pharma stock, see the ATHA Stock Forecast page.
Spark’s Take on ATHA Stock
According to Spark, TipRanks’ AI Analyst, ATHA is a Underperform.
Athira Pharma’s stock is weighed down by its financial performance, typical of an early-stage biotech firm with no revenue and high cash burn. Technical indicators show a lack of positive momentum, while valuation metrics reflect unprofitability. The stock’s prospects heavily depend on future product development and commercialization.
To see Spark’s full report on ATHA stock, click here.
More about Athira Pharma
Athira Pharma, Inc. operates in the biotechnology industry, focusing on developing therapies for neurodegenerative diseases.
Average Trading Volume: 326,348
Technical Sentiment Signal: Sell
Current Market Cap: $12.2M
Learn more about ATHA stock on TipRanks’ Stock Analysis page.